(NASDAQ: COGT) Cogent Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Cogent Biosciences's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast COGT's revenue for 2025 to be $52,455,482,301, with the lowest COGT revenue forecast at $1,101,481,998, and the highest COGT revenue forecast at $103,809,482,604. On average, 3 Wall Street analysts forecast COGT's revenue for 2026 to be $11,247,897,723, with the lowest COGT revenue forecast at $4,988,882,142, and the highest COGT revenue forecast at $18,829,107,355.
In 2027, COGT is forecast to generate $35,992,067,319 in revenue, with the lowest revenue forecast at $14,564,501,583 and the highest revenue forecast at $62,774,082,524.